Back to top
more

Protalix BioTherapeutics (PLX)

(Delayed Data from AMEX)

$1.20 USD

1.20
272,095

+0.07 (5.73%)

Updated Apr 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Protalix BioTherapeutics, Inc. [PLX]

Reports for Purchase

Showing records 1 - 20 ( 77 total )

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/14/2023

Company Report

Pages: 5

Elfabrio Approvals Accumulate; 3Q23 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

10/31/2023

Company Report

Pages: 5

Anticipating Elfabrio Commercial Traction; Raising PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PLX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/03/2021

Company Report

Pages: 5

PRX-102 Complete Response Letter Received; Lowering PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/31/2020

Company Report

Pages: 5

Final BRIDGE Trial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/30/2020

Company Report

Pages: 4

PRX-102 Approval Decision Delay; 3Q20 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/05/2020

Company Report

Pages: 4

Pegunigalsidase Expanded Access Program Established; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/12/2020

Company Report

Pages: 4

PRX-102 Regulatory Submission Accepted; 2Q20 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/27/2020

Company Report

Pages: 4

Alidornase Alfa License Non-Binding Term Sheet From SarcoMed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/08/2020

Company Report

Pages: 5

PRX-102 Submission Completion; 1Q20 Financials; Raising PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/18/2019

Company Report

Pages: 5

Positive Long-Term BRIDGE Trial Data Released; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/02/2019

Company Report

Pages: 5

Third PRX-102 Phase 3 Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/12/2019

Company Report

Pages: 4

2Q19 Financial Results Reported: Moderate Top- and Bottom- Line Miss; Anticipating PRX-102 Filing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/19/2019

Company Report

Pages: 4

Shine on BRIGHTly; Pivotal Trial Completes Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/10/2019

Company Report

Pages: 5

Accelerated Approval Application Planned in Fabry Disease; Estimates Updated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/19/2019

Company Report

Pages: 5

2018 Financial Results Reported; Revenue Recognition Restatements; Reiterate Buy and Lowering Target to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

02/21/2019

Company Report

Pages: 5

Preliminary Pivotal Pharmacokinetic Data Shines BRIGHTly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

12/18/2018

Company Report

Pages: 4

PRX-102''s Clinical Development is Chugging Along; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

12/13/2018

Company Report

Pages: 5

Decreased 2019 Revenue Expectations; Focus on Fabry Disease Pivotal Trials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

10/09/2018

Company Report

Pages: 5

Positive Preliminary PRX-102 Data Presented at Canadian Symposium; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party